LILRB2 (ES-009 Biosimilar) Recombinant Monoclonal Antibody

This recombinant monoclonal antibody is developed as a research-grade biosimilar to ES-009, targeting LILRB2 (Leukocyte Immunoglobulin-Like Receptor B2), also known as ILT4 or CD85d. LILRB2 is an inhibitory receptor predominantly expressed on myeloid cells, including monocytes, macrophages, and dendritic cells, where it functions as a critical immune checkpoint by recognizing classical and non-classical MHC class I molecules. Upon ligand binding, LILRB2 delivers immunosuppressive signals through its cytoplasmic ITIM domains, dampening immune responses and promoting tolerance. This receptor plays a significant role in tumor immune evasion, as cancer cells exploit LILRB2 signaling to suppress anti-tumor immunity. Elevated LILRB2 expression has been associated with various malignancies and contributes to the immunosuppressive tumor microenvironment.

ES-009 is a reference antibody that has been utilized in immunological research to investigate LILRB2-mediated immune regulation and its role in cancer immunotherapy. This biosimilar antibody provides researchers with a reliable tool for studying LILRB2 function in immune modulation, tumor-host interactions, and potential therapeutic interventions targeting myeloid-mediated immunosuppression in oncology and inflammatory conditions.